Eton Pharmaceuticals Secured Rights for Seizure Drug

The company obtained an exclusive U.S. licensing agreement to market the diazepam buccal film LIBERVANT.

Updated on Oct. 14, 2026 in Alzheimer’s

Eton Pharmaceuticals Secured Rights for Seizure Drug

Live Poll

Do you believe exclusive pharmaceutical licensing agreements typically result in better access to new treatments?

Eton Pharmaceuticals and Aquestive Therapeutics have entered an exclusive licensing and supply agreement for LIBERVANT. The drug is a diazepam buccal film designed to treat seizure clusters in epilepsy patients.

Why it matters

This partnership marks an expansion for Eton Pharmaceuticals into the neurology market, offering patients a potential alternative to existing nasal and rectal seizure rescue treatments.

The U.S. seizure rescue market generates over $450 million in annual value. Market research indicates that 71% of patients prefer a film-based treatment over existing nasal spray options.

The players

Eton Pharmaceuticals

This company is an American specialty pharmaceutical firm that focuses on developing and commercializing treatments for rare diseases.

Aquestive Therapeutics

This organization is a specialty pharmaceutical company focused on the development and commercialization of differentiated products for central nervous system conditions.

The details

LIBERVANT currently holds tentative FDA approval for use in specific epilepsy patients aged 2 to 5 and 12 and older. A New Drug Application is presently under review to expand this label to include patients aged 6 to 11, with a target FDA decision date set for March 2027.

The FDA granted Orphan Drug Designation to LIBERVANT in November 2016.
VALTOCO orphan drug exclusivity is scheduled to expire on January 10, 2027.
The FDA set a PDUFA target action date for the pending New Drug Application on March 29, 2027.
Eton anticipates commercial availability of LIBERVANT in April 2027.
Patent protection for the drug extends into 2038.

Health Landscape

The use of the FDA Orphan Drug Designation follows a strategic pathway for incentivizing the development of therapies for rare conditions. This approach allows companies to bridge gaps in medical care by providing specialized treatments for underserved patient populations.

Patients may eventually gain access to an alternative rescue treatment that potentially addresses concerns regarding medication portability and ease of use. This development could provide a new option for those who currently rely on existing nasal or rectal seizure rescue medications.

The takeaway

This partnership highlights the industry movement toward developing more convenient, patient-centered rescue therapies for chronic neurological conditions. Epilepsy patients and their caregivers should monitor future FDA announcements regarding the expansion of treatment options for younger pediatric groups.